2-(Acetylamino)-3-[({3-hydroxy-2-[1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidin-2-yl}carbonyl)sulfanyl]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(Acetylamino)-3-[({3-hydroxy-2-[1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidin-2-yl}carbonyl)sulfanyl]propanoic acid
• 英文别名: 2-acetamido-3-[3-hydroxy-2-(1-hydroxy-2-methylpropyl)-4-methyl-5-oxopyrrolidine-2-carbonyl]sulfanylpropanoic acid
• 化学式: C₁₅H₂₄N₂O₇S
• 分子量: 376.4
• InChiKey: DAQAKHDKYAWHCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  178
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• Compounds for reducing c-Myc in c-Myc overexpressing cancers background
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US10882863B2

  公开（公告）日：2021-01-05

  The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to administration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.

  本发明涉及可降低 c-Myc 表达并可用于癌症治疗的新化合物，特别是血液肿瘤，如侵袭性 B 细胞和 T 细胞淋巴瘤。新化合物可与辅助性 c-Myc 抑制剂如 PI3K 抑制剂、CK-1 抑制剂、Akt-抑制剂、蛋白酶体抑制剂和/或 mTor 抑制剂结合使用。c-Myc还原剂可作为先导疗法，在使用辅助癌症治疗剂之前减少或开始减少c-Myc。使用c-Myc还原剂治疗可调节c-Myc过表达癌症的疾病状态，使其恶性程度降低，更容易接受辅助癌症疗法。
• TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
  申请人：University Of Virginia Patent Foundation

  公开号：EP2897631A2

  公开（公告）日：2015-07-29
• COMBINATION THERAPIES
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150320754A1

  公开（公告）日：2015-11-12

  Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a CDK4/6 inhibitor, 2) an HDAC inhibitor, 3) a MEK inhibitor, 4) a mTOR inhibitor, 5) an AKT inhibitor, 6) a proteasome inhibitor, 7) an immunomodulator, 8) a glucocorticosteroid, 9) a BET inhibitor, 10) an epigenetic inhibitor, 11) a PI3K alpha inhibitor, 12) a topoisomerase inhibitor, or 13) an ERK inhibitor. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.
• Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20190070183A1

  公开（公告）日：2019-03-07

  The invention relates to the co-administration of select proteasome and PI3K inhibitors is useful for treating c-Myc-overexpressing cancers, particularly hematological cancers such as aggressive B- and T-cell lymphomas. In exemplified embodiments, coadministration of a dual PI3K/CK-1 inhibitor with a proteasome inhibitor synergistically increases cell death of aggressive B- and T-cell lymphomas as well as multiple myeloma over the individual or additive effect of either or both agents. This synergistic effect is associated with the previously unknown inhibition of the kinase casein kinase 1 epsilon (CK-1ε) by a PI3K inhibitor, such as TGR-1202. Accordingly, use of PI3K inhibitors that possess CK-1ε inhibition in combination with proteasome inhibitors provides a new therapy regime for treating c-Myc-overexpressing cancers, and particularly hematological cancers.
• Compounds For Reducing c-Myc In c-Myc Overexpressing Cancers Background
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20190194212A1

  公开（公告）日：2019-06-27

  The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to adminstration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.